Clinical Observation of Combined Chemotherapy of Lobaplatin and Irinotecan in the Treatment of Relapsed Advanced or Progress Small Cell Lung Cancer
|School||Zunyi Medical College,|
|Keywords||Innotecan Lobaplatin Chemotherapy Small cell lung cancer(SCLC) Relapse|
Objective:To observe the efficacy and toxicity of lobaplatin joint irinotecan-based chemotherapy on small cell lung cancer patients, rceived The EP(etoposide combined with cisplatin) or CE (etoposide combination with carboplatin) scheme chemotherapy as initial treatment, relapse or progress in6months after the treatment. In order to provide effective chemotherapy of small cell lung cancer patients’second-Line Therapy.Methods:41cases of retreatment of patients with SCLC were randomly divided into experimental and control groups. The experimental group of21cases,Of LBP30mg per square meter and pour in500ml5%glucose, diluted intravenous infusion2h,The first day. CPT-1165mg/m2in saline250ml, diluted intravenous infusion1.5h,The first day, and the eighth day dosing,,21days of a cycle. The control group of20cases, CPT-1165mg per square meter by adding0.9%sodium chloride solution of250ml was given intravenously,The first day, and the eighth day dosing. DDP25mg per square meter by adding0.9%sodium chloride solution of500ml was given intravenously.The first to the third days dosing. For21days for a cycle. We use CT scan to evaluate efficacy before treatment and after2cycles of treatment. Observed toxicity during chemotherapy.Result:The experimental group objective response rate was42.9%, The control group objective response rate was was30.1%, no significant difference between the two groups (P=0.39).The experimental group Disease control rate was61.9%,The control group Disease control rate was45%, no significant difference between the two groups (P=0.04).There were no significant difference between the two groups of Survival time (P=0.905). Differences in toxicity between the two groups, mainly as Ⅲ-Ⅳ degree reduction of platelet,the experimental group is higher than the control group(the experimental group is38.1%,the control group is20%,P=0.03).And Ⅲ-Ⅳ degree of nausea and vomiting.the control group is higher than the experimental group(the experimental group is9.5%,the control group is35%,P=0.049).Two sets of toxic reaction can be tolerated by clinical symptomatic treatment. Conclusion:A similar effect between Irinotecan united lobaplatin program and irinotecan joint cisplatin program as second-line treatment of recurrence or progression small cell lung cancer. In the control of tumor poogression, Irinotecan united lobaplatin program has certain advantage than irinotecan joint cisplatin program.,such as low toxicity,inprovement in the quality of life.